Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Glucotrack's 3-year diabetes sensor implant clears initial human safety trial | 1 | FierceBiotech | ||
Mi | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
Di | GlucoTrack Drops 24% Despite Successful First-in-Human Study Of CGM | - | RTTNews | ||
Di | Glucotrack announces pricing of $3M public offering | 1 | Seeking Alpha | ||
GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
Di | Glucotrack sets terms for $3 million public stock offering | 1 | Investing.com | ||
Di | Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering | 4 | GlobeNewswire (USA) | ||
Di | Glucotrack soars on completion of first human clinical study of continuous blood glucose monitor | 2 | Seeking Alpha | ||
Di | Glucotrack completes first-in-human continuous blood glucose monitor implant study | 3 | MassDevice | ||
Di | Glucotrack reports success in first human glucose monitor trial | 5 | Investing.com | ||
Di | Glucotrack, Inc.: Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor | 107 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen | |
30.01. | GCTK-Aktie stürzt auf 52-Wochen-Tief von 0,06 US-Dollar | 1 | Investing.com Deutsch | ||
30.01. | GCTK Stock Plummets to 52-Week Low of $0.06 Amid Market Turbulence | 3 | Investing.com | ||
30.01. | Glucotrack to execute 1-for-20 reverse stock split | 4 | Seeking Alpha | ||
30.01. | Glucotrack announces 1-for-20 reverse stock split | 2 | Investing.com | ||
30.01. | Glucotrack kündigt Aktienzusammenlegung im Verhältnis 1:20 an | 1 | Investing.com Deutsch | ||
30.01. | Glucotrack, Inc.: Glucotrack Announces Reverse Stock Split | 27 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization... ► Artikel lesen | |
29.01. | Glucotrack, Inc.: Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer | 145 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen | |
29.01. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
22.01. | How Is The Market Feeling About GlucoTrack? | 1 | Benzinga.com | ||
21.01. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ECKERT & ZIEGLER | 59,45 | +0,42 % | EQS-News: Eckert & Ziegler SE: IT-Vorfall beeinträchtigt die Kommunikationskanäle der Eckert & Ziegler SE | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Sonstiges
Eckert & Ziegler SE: IT-Vorfall beeinträchtigt die Kommunikationskanäle der Eckert & Ziegler SE
03.02.2025 / 13:23... ► Artikel lesen | |
SERNOVA | 0,134 | -1,84 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism | LONDON, Ontario and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
SYNLAB | 11,520 | +0,52 % | Synlab Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
NUGEN MEDICAL DEVICES | 0,037 | -5,67 % | Unglaubliche News! Der Super-CEO der alle Türen öffnen kann! | ||
ATOSSA THERAPEUTICS | 0,731 | -1,75 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care | ||
UNIDOC HEALTH | 0,310 | +2,65 % | Zocker, aufgepasst: InnoCan, Xorx Therapeutics, Unidoc Health | Börsenzockern, die sich derzeit an Aktien wie InnoCan, Xorx Therapeutics oder Unidoc Health versuchen, sei gesagt: Berichterstattungen zu hochspekulativen Werten dieser Art unterliegen oft massiven... ► Artikel lesen | |
PING AN HEALTHCARE | 0,770 | +0,29 % | PA GOODDOCTOR (01833): DISCLOSURE OF DEALINGS UNDER RULE 22 OF THE TAKEOVERS CODE | ||
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results | Revenues increased 14% for the quarter compared to prior year and 13% year-to-datePositive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024Year-to-date net loss... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,014 | -24,21 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,685 | +3,01 % | Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results | SALT LAKE CITY, Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development... ► Artikel lesen | |
CYTOSORBENTS | 0,961 | -2,24 % | CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue | Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor... ► Artikel lesen | |
MEDIVOLVE | 0,003 | 0,00 % | Medivolve Inc (2): Medivolve president, CEO Preiner resigns | ||
QUIDELORTHO | 41,400 | -0,48 % | QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024 | SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care... ► Artikel lesen | |
VERU | 0,572 | +4,00 % | Veru Inc.: Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction | -- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average... ► Artikel lesen |